3rd Quarter - Report — ALKERMES, INC. for ALKERMES, INC. (2015)

Firm

ALKERMES, INC.

Client

ALKERMES, INC.

Income

—

Expenses

$702,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act

Lobbyist	Covered position, as disclosed
ROBERT FORMAN	—
PETER NORMAN	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Justice, Dept of (DOJ); Natl Institute on Alcohol Abuse & Alcoholism (NIAA); Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: H.R. 2872 (114th)

Medicare/Medicaid MMM

Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015

Lobbyist	Covered position, as disclosed
ROBERT FORMAN	—
PETER NORMAN	—

Contacted: Justice, Dept of (DOJ); Natl Institutes of Health (NIH); Office of Natl Drug Control Policy (NDCP); Natl Institute on Alcohol Abuse & Alcoholism (NIAA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: S. 648 (114th)

Alcohol and Drug Abuse ALC

Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 Senate bill/HR 2578, Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)

Lobbyist	Covered position, as disclosed
ROBERT FORMAN	—
PETER NORMAN	—
DAVID TREWOLLA	—

Contacted: HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Justice, Dept of (DOJ); SENATE; Natl Institutes of Health (NIH); Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institute on Alcohol Abuse & Alcoholism (NIAA)

Bills named: H.R. 2578 (114th), H.R. 954 (114th), S. 524 (114th), H.R. 3420 (114th), S. 1695 (114th)

Pharmacy PHA

Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act

Lobbyist	Covered position, as disclosed
ROBERT FORMAN	—
PETER NORMAN	—

Contacted: Office of Natl Drug Control Policy (NDCP); Natl Institute on Alcohol Abuse & Alcoholism (NIAA); HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA); Justice, Dept of (DOJ); Natl Institutes of Health (NIH); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 639 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.